NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the first patient has been dosed in the pivotal Phase 3 Aspire study (NCT06617429) ...
“Our goal with Aspire is to confirm the safety and clinical efficacy of GTX-102 in a large ... Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try ...
See reviews below to learn more or submit your own review. How do I know I can trust these reviews about Aspire Credit Card? How do I know I can trust these reviews about Aspire Visa? 4,578,525 ...